Microbot Medical Inc. is a medical device company that focuses on transforming endovascular procedures through advanced robotic technology. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, endovascular, and neurovascular …
Full MBOT analysis →
Competitive advantage assessment
Key strengths
Conservative LeverageLeverage position is conservative vs peers (score 0.93). Balance sheet flexibility is a strategic asset for serial acquirers.
Key risks
Weak Capital Return ProfileCapital return quality is below peers (score 0.33). Low ROIC raises questions about M&A discipline and pipeline ROI.
Declining Capital ReturnsROIC durability is weak (score 0.11). Volatility or decline in returns is a leading moat erosion signal.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Where MBOT ranks in Medical Instruments & Supplies
Microbot Medical Inc. ranks #40 of 62
scored companies in Medical Instruments & Supplies by moat score — the top 65%.
The widest moat in the group is Intuitive Surgical, Inc. (ISRG)
at 86/100.
Moat scores for companies ranked near MBOT in Medical Instruments & Supplies
How MBOT scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Not measurable
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Score 23
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Not measurable
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Not measurable
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Score 68
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Score 31
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
Microbot Medical Inc. (MBOT) scores 39 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #40 of 62 scored companies in Medical Instruments & Supplies, the top 65%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Medical Instruments & Supplies. Its strongest defense is Capital Structure & Resilience (68/100) and its weakest is R&D Pipeline & Capital Returns (23/100).
How does Microbot Medical Inc. compare with other Medical Instruments & Supplies companies?
Microbot Medical Inc. ranks #40 of 62 scored companies in Medical Instruments & Supplies by moat score. The widest moat in Medical Instruments & Supplies is Intuitive Surgical, Inc. (ISRG) at 86/100. The companies ranked closest are Milestone Scientific, Inc. (MLSS) at 40 just above it and JIN MEDICAL INTERNATIONAL LTD. (ZJYL) at 38 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Medical Instruments & Supplies. The defenses are then weighted to produce the overall score out of 100.
Why is Microbot Medical Inc. scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Microbot Medical Inc.?
The Medical Devices & Diagnostics template measures 6 defenses, and MBOT scores: Pricing Power & Consumable Moat (not measurable), R&D Pipeline & Capital Returns (23), FCF Quality & Cash Conversion (not measurable), Commercial Execution (not measurable), Capital Structure & Resilience (68), Growth Durability (31). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.